Martinsried/Munich, 5 November 2015. Medigene AG (MDG1, Frankfurt, Prime Standard) announces that early clinical data from an ongoing investigator-initiated (IIT) phase I/II study with dendritic cell (DC) vaccines conducted by the Ludwig-Maximilian University Hospital, Munich (LMU), in the indication of acute myeloid leukaemia (AML) will be presented at the upcoming ASH Annual Meeting taking place from December 5 - 8, 2015 in Orlando, Florida. The poster entitled “Next-generation dendritic cell vaccination in postremission therapy of AML: results of a clinical phase I trial” will be presented by the Principal Investigator of the trial, Prof. Marion Subklewe, Professor of Internal Medicine with special Focus on Cellular Immunotherapy at the Ludwig-Maximilian University Großhadern, Munich, on December 7, 2015 at 6:00 PM - 8:00 PM (local time).
The IIT tests DC vaccines made according to Medigene’s technologies that are in-licensed from the Helmholtz Zentrum München (HMGU) which is a partner in the ongoing study. Acute myeloid leukaemia (AML) is Medigene’s lead indication in its DC vaccine programme.
Link to the abstract: https://ash.confex.com/ash/2015/webprogram/Paper85287.html
About Medigene’s DC vaccines: The platform for the development of antigen-tailored DC vaccines is the most advanced platform of the three highly innovative and complementary immunotherapy platforms of Medigene Immunotherapies. Currently, Medigene evaluates its DC vaccines in a company-sponsored phase I/II clinical trial in acute myeloid leukaemia (AML). Further studies utilizing Medigene’s DC vaccine technology include two ongoing clinical investigator-initiated trials: a clinical phase I/II trial in AML at the Ludwig-Maximilian University Hospital, Munich, and a clinical phase II trial in prostate cancer at Oslo University Hospital. Moreover, a compassionate use programme is being conducted at the Department of Cellular Therapy at Oslo University Hospital.
Dendritic cells (DCs) are the most potent antigen presenting cells of our immune system. Their task is to take up, process and present antigens on their cell surface, which enables them to activate antigen-specific T cells for maturation and proliferation. This way T cells can recognise and eliminate antigen-bearing tumour cells. Dendritic cells can also induce natural killer cells (NK cells) to attack tumour cells. The team of Medigene Immunotherapies GmbH’s scientists has developed new, fast and efficient methods for generating dendritic cells ex-vivo, which have relevant characteristics to activate both T cells and NK cells. The DC vaccines are developed from autologous (patient-specific) precursor cells, isolated from the patient’s blood, and can be loaded with tumor-specific antigens to treat different types of cancer. Medigene’s DC vaccines are in development for the treatment of minimal residual disease or use in combination therapies.
Further audio-visual education about Medigene’s DCs at: https://vimeo.com/123005832
Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative, complementary treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. Medigene concentrates on the development of personalized T cell-based immunotherapies. For more information, please visit www.medigene.com.
Contact Medigene
Julia Hofmann, Anja Clausnitzer
Tel.: +49 - 89 - 20 00 33 - 33 01
Email: investor@medigene.com
Help employers find you! Check out all the jobs and post your resume.
